TYR, tyrosinase, 7299

N. diseases: 281; N. variants: 121
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Although radioiodine labeled 4-hydroxyphenylcysteamine, which we previously developed, has good affinity for tyrosinase, an enzyme in the melanin metabolic pathway, image contrast of the melanoma:organ ratios is not sufficiently high for detection of primary melanoma and metastases at early injection times. 29413752 2018
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Blood samples from 68 patients were collected at the time of initial treatment of metastases. mRNA expression of tyrosinase and MelanA/MART1 as a surrogate marker for the presence of CTC was analyzed by real-time RT-PCR and compared with patient characteristics. 21625180 2011
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE In 321 patients we obtained data on SLN microanatomic location/tumor burden (only 7 cases had metastases <0.1 mm); in 137 we additionally analyzed 24-hour collected LY after CLND (multimarker reverse transcriptase-polymerase chain reaction [MM-RT-PCR] with primers for tyrosinase, MART1 (MelanA), and uMAGE mRNA (27.7% positive samples)].Median follow-up time was 41 months. 20607422 2010
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE The presence of tyrosinase or MelanA/MART1 transcripts is an independent prognostic factor in patients with high-risk primary uveal melanoma for subsequent development of metastases and for survival and can be used to select patients for adjuvant treatment studies. 17317826 2007
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE Melanoma patients with small micrometastases (<0.5 mm deep, <1 mm in diameter) and a low level of tyrosinase mRNA had less chances for hematogenous metastases via lymph nodes. 17204098 2007
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE We evaluated the role of a single-marker RT-PCR assay for tyrosinase mRNA in the detection of melanoma sentinel lymph node (SLN) metastases and correlated the results with long-term clinical outcome. 15459222 2004
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. 12460203 2002
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 GeneticVariation group BEFREE Thus, in logistic regression models that included age, but not advanced stage and high grade histology, TYR A1A2 was significantly associated with reduced risk of metastases (P = 0.033, OR 0.41). 11532853 2001
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Nevertheless, tyrosinase positivity in bone marrow in earlier tumor stages might indicate increased risk for the development of distant metastases. 10971051 2000
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE The detection of tyrosinase mRNA in melanoma SLN specimens by reverse transcription-polymerase chain reaction (RT-PCR) has been reported to be a more sensitive method to detect subclinical metastases, compared with histological analysis. 10340881 1999
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE The presence of tyrosinase mRNA was analysed in blood and in bone marrow samples from 20 melanoma patients with widespread clinical metastases. 10354071 1999
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE Determination of blood tyrosinase mRNA by RT-PCR and markers of tyrosinase activity (L-DOPA/L-tyrosine ratio) by HPLC have been proposed as biological tools for the detection of metastases in melanoma patients. 10340438 1999
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE The other half was submitted for molecular detection of submicroscopic metastases using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay for tyrosinase messenger RNA as a marker for the presence of melanoma cells.Patient follow-up averaged 28 months. 9801000 1998
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Expression of an extended panel of cytokine genes was investigated by reverse polymerase chain reaction (PCR) in 10 freshly excised melanoma metastases infiltrated by lymphocytes (TIL). cDNA encoding for CD3-delta and tyrosinase could be amplified in all samples, confirming the presence of T lymphocytes and melanoma cells. 8181865 1994
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Tyrosinase transcripts were found in all 29 patients with distant metastases (stage III). 8245518 1993